Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide in AML
NCT00005795Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Feb 2000
- Primary completion
- Jul 2002
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of arsenic trioxide in acute myeloid leukemia (AML), sponsored by Northwestern University. Started Feb 2000; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00005795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005795.